3rd Quarter - Report

LMH STRATEGIC SOLUTIONS for STEALTH BIOTHERAPEUTICS INC.

Period 3rd Quarter 2026 Filed Oct 19, 2026 Signed by Beth Anne Cole

Official filing
Firm
LMH STRATEGIC SOLUTIONS
Client
STEALTH BIOTHERAPEUTICS INC.
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.

LobbyistCovered position, as disclosed
ALANNA TEMME Legislative Director, U.S. Representative Jon Porter

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); SENATE

Pharmacy PHA

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.

LobbyistCovered position, as disclosed
ALANNA TEMME —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.